Copyright
©The Author(s) 2005.
World J Gastroenterol. Jul 28, 2005; 11(28): 4344-4350
Published online Jul 28, 2005. doi: 10.3748/wjg.v11.i28.4344
Published online Jul 28, 2005. doi: 10.3748/wjg.v11.i28.4344
Table 1 Baseline characteristics of all patients
| Group IA | Group IB | Group II | All patients | |
| n = 13 (37%) | n = 12 (34%) | n = 10 (29%) | n = 35 (100%) | |
| Median age (range) | 35 (21-48) | 34 (20-45) | 52 (42-68) | 38 (20-68) |
| Male (%) | 9 (69) | 11 (92) | 10 (100) | 30 (86) |
| Chinese ethnicity (%) | 13 (100) | 11 (92) | 10 (100) | 34 (97) |
| Median (range) baseline ALT, U/L | 28 (16-58) | 136 (78-1 124) | 87 (33-761) | 74(16-1 124) |
| Median (range) baseline HBV DNA, Meg/mL | 294 (120–1 680) | 253 (38–616) | 291 (20–786) | 280 (20–1 680) |
| Median baseline CPT score | NA | NA | 7.0 (5-13) | NA |
| Median (range) duration of lamivudine | ||||
| at emergence of genotypic resistance, wk | 160 (35-198) | 110 (42-212) | 62 (36-120) | 143 (35-212) |
| Follow-up after genotypic resistance, wk | 96 (48-220) | 124 (26-208) | 64 (34-102) | 102 (26-220) |
| Number (%) with phenotypic resistance | 3 (23) | 9 (75) | 6 (60) | 18 (51) |
- Citation: Dan YY, Wai CT, Lee YM, Sutedja DS, Seet BL, Lim SG. Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics. World J Gastroenterol 2005; 11(28): 4344-4350
- URL: https://www.wjgnet.com/1007-9327/full/v11/i28/4344.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i28.4344